Search PubMed⌕ Search

Biomedical subjects

Abass Alavi

Publications and source records attributed to Abass Alavi.

At least 145 records · Page 8Linked to original sources
PubMed2002

The receiver operating characteristic curve for the standard uptake value in a group of patients with bone marrow metastasis.

PURPOSE: The aim of this work was to determine the standard uptake value (SUV) threshold for differentiating malignant from benign bone lesions. MATERIAL AND METHODS: Ninety-nine bone sites in 33 patients who had undergone a 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography (FDG-PET) study for cancer evaluation were studied. In addition to FDG-PET, a bone scan and at least two of the following determinations: magnetic resonance imaging (MRI), computed tomography (CT), and x-ray were conducted in each patient. The bone lesions were considered positive for malignancy if confirmed by clinical follow-up or a high degree of suspicion based on the positive results of at least three (which must include bone scan) out of four other imaging modalities. By these criteria, 39 lesions were considered positive and 60 were considered negative. The SUV values were classified as positive or negative using 61 different values of threshold (range from 1.0 to 7.0). These results were compared with the positive criteria above and reclassified as true positive, true negative, false positive, and false negative. The true-positive fraction and false-positive fraction were calculated for each threshold value. The receiver operating characteristic (ROC) curve was drawn and the best value was determined by visual analysis. RESULTS: The SUV threshold was considered 2.5. Twenty-nine out of 39 bone lesions classified as positive showed a SUV > 2.5. Of the 10 false-negative lesions, seven showed a SUV between 1.1 and 2.0, and three were not detected. Fifty-six out of 60 lesions classified as negative showed a SUV < 2.5. Four lesions were false positive: one was a rib fracture and three were severe degenerative changes in the lumbar spine. Using an SUV threshold of 2.5, the sensitivity was 74.3% and the specificity was 93.3%. CONCLUSION: In our patient population, the optimal SUV to classify a bone lesion as malignant or benign is 2.5.

Journal Article↗
PubMed2002

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography monitoring disease progress in a patient with islet carcinoma of the pancreas.

A woman with islet cell carcinoma of the pancreas proven by biopsy at an exploratory laparotomy underwent six cycles of chemotherapy with paclitaxel and carboplatin. After the chemotherapy to monitor her primary tumor and hepatic metastases, she had three consecutive 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET) determinations that correlated with an In-111 octreotide single photon emission computer tomography. FDG-PET might have utility in monitoring islet cell carcinoma of the pancreas in evaluating metabolic changes following chemotherapy.

Journal Article↗
PubMed2002

Dynamic imaging in mild traumatic brain injury: support for the theory of medial temporal vulnerability.

OBJECTIVE: To determine whether patients with mild traumatic brain injury (TBI) and persistent postconcussive symptoms have evidence of temporal lobe injury on dynamic imaging. DESIGN: Case series. SETTING: An academic medical center. PARTICIPANTS: Twenty patients with a clinical diagnosis of mild TBI and persistent postconcussive symptoms were referred for neuropsychologic evaluation and dynamic imaging. Fifteen (75%) had normal magnetic resonance imaging (MRI) and/or computed tomography (CT) scans at the time of injury. INTERVENTIONS: Neuropsychologic testing, positron-emission tomography (PET), and single-photon emission-computed tomography (SPECT). MAIN OUTCOME MEASURES: Temporal lobe findings on static imaging (MRI, CT) and dynamic imaging (PET, SPECT); neuropsychologic test findings on measures of verbal and visual memory. RESULTS: Testing documented neurobehavioral deficits in 19 patients (95%). Dynamic imaging documented abnormal findings in 18 patients (90%). Fifteen patients (75%) had temporal lobe abnormalities on PET and SPECT (primarily in medial temporal regions); abnormal findings were bilateral in 10 patients (50%) and unilateral in 5 (25%). Six patients (30%) had frontal abnormalities, and 8 (40%) had nonfrontotemporal abnormalities. Correlations between neuropsychologic testing and dynamic imaging could be established but not consistently across the whole group. CONCLUSIONS: Patients with mild TBI and persistent postconcussive symptoms have a high incidence of temporal lobe injury (presumably involving the hippocampus and related structures), which may explain the frequent finding of memory disorders in this population. The abnormal temporal lobe findings on PET and SPECT in humans may be analogous to the neuropathologic evidence of medial temporal injury provided by animal studies after mild TBI.

Adult↗
PubMed2002

Positron emission tomography imaging in nonmalignant thoracic disorders.

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

Animals↗
PubMed2002

Whole-body FDG-PET imaging in the management of patients with cancer.

Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is increasingly used for the management of patients with cancer. The technique is now well accepted by most physicians as an effective complement to the existing imaging modalities. For many malignancies, PET achieves high sensitivity and specificity. The critical role of this powerful technique is realized increasingly in the day-to-day practice of oncology. This is particularly true for the management of patients with non-small-cell lung cancer (NSCLC). The contribution of PET for the selection of patients eligible for curative treatments in this setting is well established. Convincing data also exist to support the use of PET for evaluating patients with recurrent colorectal carcinoma, for staging and restaging lymphomas, and for diagnosing recurrent thyroid carcinoma in the presence of elevated thyroglobulin and negative 131I scans. Other indications include staging of various recurrent malignancies, such as breast cancer, melanoma, and head and neck and gynecologic carcinomas. Existing data are limited for the determination of the impact of PET in certain malignancies, and further studies, which should include outcome information, will allow clarification of the role of this modality for such indications. Despite the small number of studies specifically designed to assess changes in management plans for some malignancies after performing PET the overall favorable results are encouraging enough at this time to include this modality as an essential element of the practice of modern oncology. Finally, the evolving role of PET imaging as a predictor of response after local or systemic treatment may add a major dimension to the application of this novel technique.

Fluorodeoxyglucose F18↗
PubMed2002

Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders.

Functional brain imaging using 18F fluorodeoxyglucose (FDG) and positron emission tomography (PET) has greatly enhanced our understanding of brain function both in normal conditions as well as in a wide variety of neuropsychiatric disorders. We review the uses of FDG PET in the diagnosis, management, and follow-up of patients with neuropsychiatric disorders. This article will also explore what FDG-PET imaging has revealed in these neuropsychiatric disorders and how these findings relate to both research and clinical applications.

Blood Glucose↗
PubMed2002

18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation.

During the past decade, 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) has rapidly evolved from a pure research modality to a clinical necessity. FDG-PET was introduced to determine the state of brain function in physiologic and pathologic states. Its use as a powerful tool to diagnose, stage, and monitor patients with a variety of malignancies has been truly revolutionary. However, FDG is a nonspecific tracer and it has been found to accumulate at sites of infection and inflammation. It is becoming evident that PET imaging will play a major role in the treatement of patients with suspected infection and inflammation. PET has been shown to be particularly valuable in the evaluation of chronic osteomyelitis, infected prostheses, sarcoidosis, fever of unknown origin, and acquired immunodeficiency syndrome. Because of its ability to quantitate the rate of FDG uptake, PET may prove to be a powerful modality for the monitoring of disease activity and response to therapy. Novel PET tracers are being tested for imaging infection and inflammation that may further enhance the role of this technique in the appropriate clinical setting. PET imaging to detect and characterize infection and inflammation may become a major clinical indication in the day-to-day practice of medicine.

Acquired Immunodeficiency Syndrome↗
PubMed2002

18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors.

It has been reported that there is a high correlation between fluorodeoxyglucose (FDG) uptake in the aorta and macrophage content of atherosclerotic lesions in an experimental rabbit model. We evaluated the frequency of FDG uptake in the large arteries in relation to the atherogenic risk factors. We also investigated whether FDG uptake of the large arteries is related to clinically known coronary artery disease. The presence of FDG uptake was assessed in the abdominal aorta (AA), iliac (IA), and proximal femoral arteries (FAs) in 156 patients. Medical history of the atherogenic risk factors (age, cigarette smoking, hypertension, diabetes, high cholesterol, and obesity) and coronary artery disease (CAD) was identified for each patient. The frequency of vascular FDG uptake was compared between the patients without risk factors (Group I, 23 patients) and those with at least 1 risk factor (Group II, 133 patients). The correlation of each risk factor and known CAD with arterial FDG uptake was also assessed in the 3 different arteries. There was a significant difference in the frequency of FDG uptake between the 2 groups for the FA (22% vs 70%) and IA (30% vs 54%), but not for the AA (35% vs 53%). Among all risk factors, age was the most significant and consistent factor correlating with FDG uptake in all 3 arteries. Hypercholesterolemia also correlated consistently with FDG uptake in all 3 arteries. The correlation between the remaining risk factors and arterial FDG uptake was rather artery specific than consistent throughout all 3 arteries. A higher frequency of FDG uptake in the FA was seen in patients with CAD compared with those without CAD. Not all risk factors correlated with FDG uptake in different arteries. Among the risk factors, age and hypercholesterolemia most consistently correlated with FDG uptake in the AA, and the IA and proximal FAs. The positive correlation of arterial FDG uptake with the atherogenic risk factors suggested a promising role for FDG-PET imaging in the diagnosis of atherosclerosis and follow-up after treatment intervention.

Adolescent↗
PubMed2002

Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas.

18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is a unique functional/metabolic imaging modality that is efficacious in nodal staging and detection of extranodal involvement for a variety of lymphomas. We report its novel use in evaluating tumor burden and response to therapy in two patients with cutaneous lymphomas. A 24-year-old woman with aggressive subcutaneous panniculitic T-cell lymphoma associated with fever, arthralgias, lymphadenopathy, mild anemia, and widespread painful lesions refractory to multiple treatment strategies exhibited intense uptake of a glucose analogue at sites of clinically apparent (and clinically imperceptible) disease. Denileukin diftitox therapy resulted in clinical remission, and a repeat PET scan failed to detect residual foci of malignancy. A 38-year-old man with a more indolent multifocal primary cutaneous follicle center B-cell lymphoma characterized by few systemic symptoms and slowly evolving lesions demonstrated only mild glucose analogue uptake at sites of disease. Remission was achieved by radiotherapy and intravenous rituximab, and confirmed by a repeat PET scan. Extracutaneous disease was not evident in either patient by this technique. These preliminary data suggest that FDG-PET may be useful in determining disease activity at the time of initial diagnosis, after treatment, and evaluating a suspected recurrence.

Adult↗
PubMed2002

Detection of small bowel involvement by mantle cell lymphoma on F-18 FDG positron emission tomography.

F-18 fluorodeoxyglucose positron emission tomography (FDG PET) is highly sensitive and specific for the detection of nodal and extranodal disease in patients with malignant lymphoma. However, no previous reports have shown lymphomatous involvement of the small bowel that was recognized on the basis of FDG-PET imaging findings. The authors present two cases of clinically unsuspected small bowel involvement by mantle cell lymphoma that were initially detected on FDG PET.

Colonoscopy↗
PubMed2002

Tc-99m sulfur colloid and Tc-99m tagged red blood cell methods are comparable for detecting lower gastrointestinal bleeding in clinical practice.

PURPOSE: The objective of this study was to determine whether the Tc-99m red blood cells (Tc-99m RBC) method has a true advantage over the Tc-99m sulfur colloid (Tc-99m SC) technique in a busy clinical practice for detecting and localizing lower gastrointestinal bleeding sites. METHODS: Three hundred fifty-nine consecutive gastrointestinal bleeding studies performed during the past 4 years were reviewed retrospectively. One hundred ninety-three scans were obtained with Tc-99m SC (scan duration, 30 minutes) and 138 studies were performed after the administration of Tc-99m RBC (scan duration, 1 hour). In addition, 28 examinations with Tc-99m SC were followed immediately by Tc-99m RBC scans for a duration of several hours. The results of the two methods were analyzed and the performance of the two techniques was compared. RESULTS: Among 193 scans performed using the Tc-99m SC method, 47 (24.4%) successfully identified the location of the bleeding site, whereas in 138 scans performed using Tc-99m RBC, 38 (27.5%) were successful for this purpose. In the remaining 28 scans in which the Tc-99m SC scan was followed by the Tc-99m RBC study, only 4 (14.3%) positive bleeding sites were identified after a prolonged imaging period. DISCUSSION: The theoretical advantages of the Tc-99m RBC technique compared with the Tc-99m SC method cannot be substantiated by this study. Our findings suggest that the efficacy of these two methods is nearly equal at a practical level. CONCLUSION: The simpler and cost-effective Tc-99m SC method is as efficient as the Tc-99m RBC method when the scanning time is limited to 1 hour and optimal imaging and interpretation schemes are used.

Adult↗
PubMed2002

Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules.

PURPOSE: Fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging has been used extensively to diagnose cancer with high rates of sensitivity and specificity. One of its applications is to distinguish benign from malignant pulmonary nodules. It is common to observe colonic uptake on whole-body FDG-PET images. Because patients with lung cancer also tend to be in the age group with the highest incidence of colon cancer, the authors tried to assess the efficacy of FDG-PET for detecting occult colon cancer in patients referred for the evaluation of lung nodules. METHODS: The records of 500 consecutive patients referred for the evaluation of pulmonary nodules were reviewed retrospectively. Among the patients, 197 had no previous clinical or radiographic evidence of abnormalities in the gastrointestinal tract, and none had been found to have any cancer before undergoing an FDG-PET study. All colon lesions were verified either by histologic analysis or by clinical course. RESULTS: Among the 197 patients analyzed, 59 had diffuse colonic uptake in various segments of the colon. Seventeen of the patients had focal colonic uptake, five of which were proved to be colon cancer. CONCLUSIONS: The routine use of FDG PET to characterize lung lesions significantly increases the probability of detecting unexpected extrathoracic disease. In these patients, the incidental finding of colon cancer had an important effect on their treatment and may prove to be very cost-effective.

Adenocarcinoma↗